Key TakeawaysThe FDA approved a new drug for the treatment of recurrent or metastatic cervical cancer.This comes after the medication received accelerated approval in 2021.Experts say that this drug and others like it mark an exciting development in the treatment of cervical cancer.
Key Takeaways
The FDA approved a new drug for the treatment of recurrent or metastatic cervical cancer.This comes after the medication received accelerated approval in 2021.Experts say that this drug and others like it mark an exciting development in the treatment of cervical cancer.
After receiving accelerated approval from the Food and Drug Administration (FDA) in 2021, Tivdak (tisotumab vedotin-tftv) receivedtraditional approval last week.The drug is for those with recurrent or metastatic cervical cancer who are on or who have received chemotherapy, a group of patients that, according to experts, has had less-than-ideal treatment options previously.
Marta Crispens, MD, a professor and director in the division of gynecologic oncology at Vanderbilt University Medical Center, said that cervical cancer research has vastly improved from when she completed her fellowship training in 1998.
“We had really not seen significant advances in the treatment of this disease until very recently,” Crispens said. “If a patient had advanced or recurrent disease, we really just had some standard chemotherapy options that honestly weren’t very effective and had a lot of side effects.”
The drug, which belongs to a group of medications known asantibody-drug conjugates, is in line to replace older medications like topotecan and gemcitabine. Tivdak’s role is to disrupt the replication of the cell. Joshua G. Cohen, MD, medical director of gynecologic cancer at City of Hope Orange County, likens the drug’s structure to a dumbbell and its role to that of a smart bomb.
“Picture the way a dumbbell is shaped: one end is like a receptor with a target. We have the linker—which is the straight part of the dumbbell—and on the other side, the killing agent,” Cohen said. “That agent blocks something called microtubules—the skeletons of cancer cells—from continuing to divide.”
The medication is given intravenously over a period of thirty minutes every three weeks.
FDA approval comes after a randomized clinical trial which confirmed the effectiveness of the drug. Patients who were taking Tivdak lived two months longer at the median than their counterparts who received chemotherapy.
Managing Side Effects
These side effects are something that medical practitioners have to keep in mind when they decide to prescribe this course of treatment, particularly eye damage,Noelle Cloven, MD, an associate professor at Texas Christian University’s Burnett School of Medicine and a gynecologic oncologist with Texas Oncology at the Fort Worth Cancer Center, told Verywell.
“Patients who are on this treatment have to use eyedrops to protect from getting dry eyes, eye irritation events, and vision disturbances,” she said. “These side effects are reversible with different things like holding the drug or reducing the dose.”
Peripheral neuropathy, a condition where your extremities can begin to tingle or go numb, can be treated via medications like gabapentin.
Getting New Treatments May Require Self-Advocacy
Cloven, whose department had patients who participated in the trial that led to the FDA approval, said that clinical trials are a key component in improving patient outcomes for those with cervical cancer.
“Always be on the lookout for clinical trials. It’s really important that patients are aware,” she said. “Often, patients don’t need to travel; [the medication] can be administered close to home.”
Cloven and Cohen both emphasized that good treatment often requires self-advocacy and research about treatment options.
Cohen said there also needs to be a focus on prevention.
“We need to do a better job in the U.S. with vaccination.HPV vaccination is the best way to prevent cervical cancer,” he said.
3 SourcesVerywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Food and Drug Administration.FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer.National Library of Medicine: DailyMed.Tivdak—tisotumab vedotin injection, powder, for solution[drug label].Pfizer.FDA grants full approval for Tivdak to treat recurrent or metastatic cervical cancer.
3 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Food and Drug Administration.FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer.National Library of Medicine: DailyMed.Tivdak—tisotumab vedotin injection, powder, for solution[drug label].Pfizer.FDA grants full approval for Tivdak to treat recurrent or metastatic cervical cancer.
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
Food and Drug Administration.FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer.National Library of Medicine: DailyMed.Tivdak—tisotumab vedotin injection, powder, for solution[drug label].Pfizer.FDA grants full approval for Tivdak to treat recurrent or metastatic cervical cancer.
Food and Drug Administration.FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer.
National Library of Medicine: DailyMed.Tivdak—tisotumab vedotin injection, powder, for solution[drug label].
Pfizer.FDA grants full approval for Tivdak to treat recurrent or metastatic cervical cancer.
Meet Our Medical Expert Board
Share Feedback
Was this page helpful?Thanks for your feedback!What is your feedback?OtherHelpfulReport an ErrorSubmit
Was this page helpful?
Thanks for your feedback!
What is your feedback?OtherHelpfulReport an ErrorSubmit
What is your feedback?
